Previous 10 | Next 10 |
Hot off its 1-for-15 reverse stock split on August 26, Mind Medicine (NASDAQ: MNMD) shares are hovering near $11.50, and the market's reaction to the move has been muted at best. The psychedelic therapy developer's stock is still down by more than 72.7% in the last 12 months thanks ...
Summary MindMed is burning through its cash pile without generating any IP. The MEME stock rally is a confusing but illuminating story into some key players in this stock. MindMed may never generate any revenue without a new drug discovery or change in strategic direction. ...
As an early stage biotech devoted to developing psychedelic medicines, Mind Medicine (NASDAQ: MNMD) is a risk lover's paradise encapsulated into a stock. The company won't have any therapies on the market for quite some time, assuming it can ever successfully develop them at all. Bu...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/PhotobyTawat Humanigen (NASDAQ: HGEN ) stock is heading lower on Monday as investors react to a delisting notice from the Nasdaq Exchange . According to a filing with the U.S. Secur...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: arfa adam / Shutterstock.com Clarus Therapeutics (NASDAQ: CRXT ) stock is falling hard on Monday as investors prepare for the stock to be delisted later this week . Shares of CRXT stock will no longer...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Psychedelics have been in the national spotlight recently and MindMed (NASDAQ: MNMD ) stock has been enjoying the ride. Its mission is to address patient needs through “the therapeutic potential of psychedeli...
MindMed Completes 1-for-15 Reverse Share Split Canada NewsWire - Common shares will begin trading on a split-adjusted basis at market open on August 29, 2022 - NEW YORK , Aug. 26, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MM...
MindMed ( NASDAQ: MNMD ) has dosed the first patient in a phase 2b trial examining a pharmaceutically optimized form of LSD for the treatment of general anxiety disorder . In the trial of MM-120 that plans to enroll 200, participants will receive a single dose of up to...
MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder Canada NewsWire NEW YORK , Aug. 25, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in MindMed (NASDAQ: MNMD ) are seeing another day of impressive price action. This morning, MNMD stock surged more than 18% higher on a couple of interesting catalysts. However, in early aft...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
2024-07-26 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...
Cluster headaches are headaches characterized by severe pain that often occurs on a side of the head or behind one eye. These headaches may last anywhere between 15 minutes to 3 hours and usually strike suddenly, often recurring more than once a day. The pain experienced by patients is... R...